Navigation Links
Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension
Date:10/9/2007

In rats with portal hypertension, ultraClow-dose aspirin has shown a normalizing effect of platelet-endothelial cell alterations and bleeding time. Further, this effect is mediated by Cyclooxygenase 2 inhibition.

This study, performed by a team led by Professor C. Doutremepuich, is described in a research article to be published in the October 14 issue of the World Journal of Gastroenterology.

Portal hypertension is a major complication of chronic liver disease, and bleeding is one of its most severe problems, leading often to death. Currently no treatment is used to modify the altered platelet activity observed in this pathology.

Ultra-low-dose aspirin has a prothrombotic effect that is the opposite of that observed with usual doses for the prevention of stroke or heart attack. The antithrombotic properties of low-dose aspirin are achieved by the inhibition of COX 1 in platelets. Aspirin is the most widely used antithrombotic agent. Previous research in rats has shown that the prothrombotic properties of ultra-low-dose aspirin are not mediated by platelets but by endothelial cells, and as such they have the potential of reversing the platelet-endothelial cell interaction alterations observed in portal hypertension.

In the view of the authors, to date no clear explanation has existed to elucidate the effect of such a small dose of aspirin, and no mechanism has been found to explain this contradictory action.

The prothrombotic effects of COX 2 inhibitors became evident in 2004 when one of the most widely accepted non-steroidal anti-inflammatory drugs was withdrawn from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Only aspirin has been demonstrated to have a prothrombotic effect at a very low dose.

In an elegant study design, including a model of in vivo Laser induced thrombosis in rats, bleeding time and prostanoid dosing, this research was performed by doctors from the Laboratory of Haematology of the Faculty of Pharmacy at the University of Bordeaux 2, France, Laboratoires Boiron and from the CEBBAD, Universidad Maimonides, Buenos Aires, Argentina.

Further research should explain the consequences of COX 2 inhibition produced by ultra-low doses of aspirin.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
86-108-538-1901
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy
2. Aspirin reduces cardiovascular risks in men and women -- but differently
3. Aspirin discovery may improve cancer treatments
4. Circles Of DNA Might Help Predict Success Of Stem Cell Transplantation
5. Antibiotic might fight HIV-induced neurological problems
6. Newly discovered pathway might help in design of cancer drugs
7. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
8. Compound might defeat African sleeping sickness, clinical trial beginning this month
9. Stem cells electric abilities might help their safe clinical use
10. Software might revolutionize glucose monitoring in critically ill patients
11. Free-radical busting antioxidants might not promote healthy hearts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2016)... NEW YORK , Jan. 7, 2016 ... as regional markets for biometric technologies and devices, identifying ... application market for various types of biometric devices. Includes ... report to: Identify newer markets and explore the ... of biometric devices. Examine each type of biometric technology, ...
(Date:1/7/2016)... MIAMI , Jan. 7, 2016  A United ... became the first court in the country to interpret ... landmark lawsuit to go forward against the photo website ... LLP. BRIAN NORBERG vs. SHUTTERFLY, INC.; ... the plaintiff alleges that Shutterfly violates the Illinois Biometric ...
(Date:1/6/2016)... , Jan. 6, 2016 Based on ... Frost & Sullivan recognizes MorphoTrak, LLC, a U.S. ... American Frost & Sullivan Company of the Year ... scanning technology, Morpho Wave™ , has consolidated the ... fingerprint biometrics market. Morpho Wave is a ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu ... quad LC-MS, host live demos and poster sessions, and present on the analysis ... conference takes place March 6 to 10 at the Georgia World Congress Center ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... British Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... today announced that it will present at the 18 ... Monday, February 8, 2016 at 10:00 a.m. EST in ... Bacha , DelMar,s president and CEO, will provide an update ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
Breaking Biology Technology: